Adverse event following immunisation of adsorbed-inactivated Coronavac (Sinovac) and ChAdOx1 nCOV-19 (Astra Zeneca) of COVID-19 vaccines

Adverse event following immunisation of adsorbed-inactivated Coronavac (Sinovac) and ChAdOx1 nCOV-19 (Astra Zeneca) of COVID-19 vaccines

Countries around the world organised mass vaccinations using various types of vaccines against COVID-19, like inactivated viruses and mRNA. The study aimed to look at adverse events following immunisation (AEFI) of Coronavac® (SIN) and ChAdOx1 nCOV-19 ® (AZ) COVID-19 vaccines in Indonesia. Subjects...

Full description

Saved in:
Bibliographic Details
Published in:Medical journal of Malaysia Vol. 79; no. 5; p. 507
Main Authors: Simatupang, A, Sitompul, Y R M B, Simanungkalit, B, Kurniyanto, K, Achmad, L N, Sitompul, F, Mahmud, S M, Suarthana, E
Format: Journal Article
Language:English
Published: Malaysia 01-09-2024
Subjects:
Adolescent
Adult
Aged
ChAdOx1 nCoV-19
COVID-19 - prevention & control
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - adverse effects
Female
Humans
Indonesia
Male
Middle Aged
SARS-CoV-2
Surveys and Questionnaires
Vaccines, Inactivated - administration & dosage
Vaccines, Inactivated - adverse effects
Young Adult
Indonesia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Countries around the world organised mass vaccinations using various types of vaccines against COVID-19, like inactivated viruses and mRNA. The study aimed to look at adverse events following immunisation (AEFI) of Coronavac® (SIN) and ChAdOx1 nCOV-19 ® (AZ) COVID-19 vaccines in Indonesia. Subjects who received SIN or AZ vaccines were sent questionnaires twice: after they received the first and the second doses of vaccine, respectively. AEFI data on the first- and second-day post-vaccination were collected and analyzed descriptively. A total of 1547 people vaccinated with SIN vaccine, 529 (33.3%) responded to the first-dose and 239 (47%) to the second-dose questionnaires, whereas 936 people vaccinated with AZ vaccine, 483 (51.6%) answered the firstdose and 123 (25%) to the second-dose questionnaires. Some important AEFIs on the first- and second-day post receiving SIN vs. AZ vaccination were as follows: fever 4% vs 59%; pain at the injection site 27% vs 87%; redness and swelling at the injection site 4% vs 18%; nausea 5% vs 30%; diarrhea 1.8% vs 5.7%, respectively. SIN seemed to have fewer AEFIs than AZ. Apart from different vaccine materials and excipients, the gap in AEFIs between SIN and AZ could be caused by the distinct population where AZ recipients were more exposed to COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-5283